Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Burkitt Lymphoma 3Urogenital Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1Lymphoma 1Lung Neoplasms 1Leukemia, Biphenotypic, Acute 1HTLV-I Infections 1Composite Lymphoma 1Colitis 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

prednylidene 1deltacortene 1Vincristine 1Specimen Handling 1Prednisone 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × HTLV-I Infections × prednylidene × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡